Key Takeaways
- • Recordati's board endorsed a €10.7bn take-private offer from CVC Capital Partners and Groupe Bruxelles Lambert at €51.29 per share, with six of 10 directors voting in favor despite opposition from four independent directors.
- • The four independent directors objected to the offer price, arguing it fails to reflect the Italian pharmaceutical company's intrinsic value and long-term growth potential, though they acknowledged the strategic rationale for going private.
- • CVC already controls 46.8% of Recordati through a holding company since 2018 and is seeking to acquire the remaining publicly held shares to complete a full delisting.
- • The board emphasized that private ownership would unlock greater strategic flexibility for long-term acquisitions and growth initiatives without the constraints of public market pressures.
- • Recordati's share price closed at €51.30 on the day of the announcement, nearly aligned with the offer price, and has appreciated 5.7% year-to-date amid broader Italian pharmaceutical sector consolidation.
Summary
A majority of Recordati's board has recommended acceptance of CVC Capital Partners and Groupe Bruxelles Lambert's €10.7bn take-private proposal, marking a significant step toward delisting the Italian pharmaceutical company from Milan's stock exchange. Six of the company's 10 directors concluded that the €51.29 per share all-cash offer represents fair value for shareholders, according to Reuters reporting on the board decision.
However, the endorsement came with notable internal dissent. Four independent directors voted against the transaction, asserting that the offer price inadequately compensates shareholders for Recordati's intrinsic value and medium-to-long-term growth trajectory. Despite their opposition on valuation grounds, these directors acknowledged the strategic appeal of private ownership and the operational advantages it could provide, suggesting the disagreement centered on price rather than deal rationale.
CVC's position as a controlling shareholder since 2018—holding 46.8% through a dedicated holding company—has positioned the firm to orchestrate this take-private following the submission of a non-binding acquisition proposal earlier in 2026. The transaction, announced in May, reflects accelerating consolidation within Italy's pharmaceutical sector and the broader trend of private equity firms taking established healthcare companies private to optimize capital allocation and pursue acquisition strategies.
Recordati, which traces its origins to a family pharmacy founded over a century ago in central Italy, has evolved into an international pharmaceutical enterprise with diversified operations spanning primary care, consumer healthcare, and orphan drug treatments. The board's rationale for recommending the transaction centered on the enhanced strategic flexibility that private ownership would enable, particularly regarding long-term M&A activities and growth investments free from quarterly earnings pressures and equity market scrutiny.
Market reaction remained measured, with Recordati shares closing at €51.30 on the announcement day—essentially at parity with the offer price—suggesting limited upside expectations. The stock has gained approximately 5.7% since the beginning of the year, reflecting both deal-related momentum and sector tailwinds.
However, the endorsement came with notable internal dissent. Four independent directors voted against the transaction, asserting that the offer price inadequately compensates shareholders for Recordati's intrinsic value and medium-to-long-term growth trajectory. Despite their opposition on valuation grounds, these directors acknowledged the strategic appeal of private ownership and the operational advantages it could provide, suggesting the disagreement centered on price rather than deal rationale.
CVC's position as a controlling shareholder since 2018—holding 46.8% through a dedicated holding company—has positioned the firm to orchestrate this take-private following the submission of a non-binding acquisition proposal earlier in 2026. The transaction, announced in May, reflects accelerating consolidation within Italy's pharmaceutical sector and the broader trend of private equity firms taking established healthcare companies private to optimize capital allocation and pursue acquisition strategies.
Recordati, which traces its origins to a family pharmacy founded over a century ago in central Italy, has evolved into an international pharmaceutical enterprise with diversified operations spanning primary care, consumer healthcare, and orphan drug treatments. The board's rationale for recommending the transaction centered on the enhanced strategic flexibility that private ownership would enable, particularly regarding long-term M&A activities and growth investments free from quarterly earnings pressures and equity market scrutiny.
Market reaction remained measured, with Recordati shares closing at €51.30 on the announcement day—essentially at parity with the offer price—suggesting limited upside expectations. The stock has gained approximately 5.7% since the beginning of the year, reflecting both deal-related momentum and sector tailwinds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.